Seroflo: Advanced Dual-Therapy Inhaler for Asthma and COPD Control
Seroflo
| Product dosage: 250mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $110.00 | $110.00 (0%) | 🛒 Add to cart |
| 2 | $94.50 | $220.00 $189.00 (14%) | 🛒 Add to cart |
| 3 | $89.00 | $330.00 $267.00 (19%) | 🛒 Add to cart |
| 4 | $86.25 | $440.00 $345.00 (22%) | 🛒 Add to cart |
| 5 | $84.80 | $550.00 $424.00 (23%) | 🛒 Add to cart |
| 6 | $83.67 | $660.00 $502.00 (24%) | 🛒 Add to cart |
| 7 | $83.00 | $770.00 $581.00 (25%) | 🛒 Add to cart |
| 8 | $82.38
Best per inhaler | $880.00 $659.00 (25%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Seroflo represents a significant advancement in respiratory medicine, combining two proven therapeutic agents into a single, convenient inhaler. This fixed-dose combination inhaler integrates a potent inhaled corticosteroid (ICS) with a long-acting beta2-agonist (LABA), offering superior anti-inflammatory and bronchodilatory effects compared to monotherapy. Designed for maintenance treatment of persistent asthma and COPD, Seroflo works by reducing airway inflammation and preventing bronchoconstriction, providing comprehensive respiratory management. Its metered-dose inhaler delivery system ensures consistent dosing and deep lung deposition, making it a cornerstone therapy for patients requiring step-up treatment.
Features
- Fixed-dose combination of fluticasone propionate (ICS) and salmeterol xinafoate (LABA)
- Metered-dose inhaler with dose counter for accurate administration
- Multiple strength configurations (e.g., 50/25 mcg, 125/25 mcg, 250/25 mcg per puff)
- Hydrofluoroalkane (HFA) propellant with minimal environmental impact
- Designed for twice-daily maintenance therapy
- Consistent particle size distribution for optimal lung deposition
Benefits
- Provides dual-mechanism control of inflammation and bronchoconstriction
- Reduces frequency and severity of asthma exacerbations
- Improves lung function measurements (FEV1) within 30 minutes of administration
- Decreases reliance on rescue inhalers for symptom control
- Offers convenient twice-daily dosing regimen for improved adherence
- Demonstrates superior symptom control compared to monocomponent therapies
Common use
Seroflo is indicated for the maintenance treatment of asthma in patients aged 12 years and older where combination therapy is appropriate. It is also approved for maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, who have a history of exacerbations. The medication is not intended for relief of acute bronchospasm but rather for long-term control of respiratory symptoms. Physicians typically prescribe Seroflo when medium-to-high dose ICS therapy alone provides inadequate control or when asthma severity warrants initial combination therapy.
Dosage and direction
The recommended dosage of Seroflo must be individualized based on disease severity and previous therapy. For asthma: The usual starting dose is 2 puffs twice daily (approximately 12 hours apart), with strength determined by symptom severity (50/25 mcg, 125/25 mcg, or 250/25 mcg). For COPD: The recommended dose is 2 puffs of Seroflo 250/25 mcg twice daily. Patients should prime the inhaler before first use or if not used for more than 4 weeks by releasing 4 test sprays into the air away from the face. Rinse mouth with water after each use to reduce the risk of oropharyngeal candidiasis.
Precautions
Patients using Seroflo should be monitored regularly for height in children and adolescents due to potential growth suppression. Caution is advised in patients with tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Systemic corticosteroid effects may occur, particularly at higher doses, including adrenal suppression, reduction in bone mineral density, and ocular effects (cataracts, glaucoma). Paradoxical bronchospasm may occur immediately after dosing, requiring alternative therapy. Patients should not discontinue Seroflo abruptly without physician supervision.
Contraindications
Seroflo is contraindicated in patients with known hypersensitivity to fluticasone propionate, salmeterol, or any component of the formulation. It should not be used as primary treatment for status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. The medication is contraindicated for relief of acute symptoms, and extra doses should not be used for that purpose. Concomitant use with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) is contraindicated due to increased systemic corticosteroid and cardiovascular effects.
Possible side effects
Common adverse reactions (≥1%) include: upper respiratory tract infection, pharyngitis, headache, upper respiratory inflammation, sinusitis, hoarseness, oral candidiasis, throat irritation, viral respiratory infections, and cough. Less frequent but serious side effects may include: pneumonia in COPD patients, cardiovascular effects (tachycardia, palpitations, chest pain), systemic corticosteroid effects, hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm), reduced bone mineral density, growth suppression in children, and eye disorders (cataracts, glaucoma). Patients should report any unusual symptoms promptly.
Drug interaction
Significant interactions may occur with strong cytochrome P450 3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) which may increase fluticasone systemic exposure and cardiovascular effects of salmeterol. Beta-blockers may antagonize the effects of salmeterol and produce severe bronchospasm in asthma patients. Diuretics may potentiate hypokalemia or ECG changes. Concomitant use with other sympathomimetic agents may potentiate sympathetic effects. MAO inhibitors and tricyclic antidepressants may potentiate cardiovascular effects. Theophylline may increase the risk of hypokalemia or cardiovascular effects.
Missed dose
If a dose of Seroflo is missed, patients should take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never take extra doses to make up for a missed dose. Doubling the dose may increase the risk of adverse effects without providing additional therapeutic benefit. Consistent use as prescribed is important for optimal disease control.
Overdose
Overdose may produce symptoms consistent with beta2-agonist overdose (tachycardia, arrhythmias, tremor, headache, muscle cramps, nausea, dizziness, hypertension, hypokalemia, hyperglycemia) and/or corticosteroid overdose (hypercorticism, adrenal suppression). There is no specific antidote for Seroflo overdose. Treatment should be supportive and symptomatic, with cardiac monitoring and assessment of electrolyte levels. Consider discontinuation of the medication and implement appropriate symptomatic therapy. Dialysis is not appropriate for removing these medications from the system.
Storage
Store Seroflo inhaler at room temperature between 15-30°C (59-86°F). Avoid freezing and exposure to extreme heat or direct sunlight. The canister should not be punctured, broken, or burned, even when empty. Keep the inhaler with the mouthpiece down to prevent clogging. The dose counter indicates how many doses remain; discard the inhaler when the counter reads “0” or 3 months after removal from the foil pouch, whichever comes first. Keep out of reach of children and pets.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Seroflo is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary, and only your physician can determine the appropriate treatment for your specific condition. Patients should not adjust dosage or discontinue medication without consulting their healthcare provider. Always read the accompanying patient information leaflet for complete prescribing information.
Reviews
Clinical studies demonstrate that Seroflo provides significant improvement in lung function and quality of life measures compared to monotherapy. In a 12-week randomized controlled trial, asthma patients using Seroflo 250/25 mcg showed a 25% greater improvement in morning PEFR compared to fluticasone alone. COPD studies reported a 30% reduction in exacerbation frequency versus placebo. Real-world evidence supports these findings, with patients reporting improved symptom control and reduced rescue medication use. However, some patients note the importance of proper inhaler technique training for optimal results, and a minority report oral thrush despite rinsing.